DIAGENS-B March 2026 Monthly Return Shows Stable Share Base and Public Float Compliance

Bulletin Express04-22

Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) filed a resubmitted monthly return with Hong Kong Exchanges and Clearing on 22 April 2026, covering the period to 31 March 2026—the company’s first reporting period after its Main Board debut on 30 March 2026.

Total registered share capital remained unchanged at 88.88 million H shares with a par value of RMB 1 each. No issues, cancellations, conversions, repurchases or treasury share movements occurred during the period, leaving issued shares and treasury shares at 88.88 million and zero, respectively.

The company confirmed that its public float exceeded the initial prescribed threshold of 17.05% of issued H shares, meeting Main Board Rule 13.32B requirements.

DIAGENS-B reported no outstanding share options, warrants, convertible instruments or other equity-linked agreements as of 31 March 2026.

Executive Director Song Ning signed the statutory confirmations that all regulatory, legal and listing conditions related to the company’s securities have been fully observed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175371587?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175371587","market":"hk","top_or_hot":-1,"title":"DIAGENS-B March 2026 Monthly Return Shows Stable Share Base and Public Float Compliance","media":"Bulletin Express","content":"<p>Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) filed a resubmitted monthly return with Hong Kong Exchanges and Clearing on 22 April 2026, covering the period to 31 March 2026—the company’s first reporting period after its Main Board debut on 30 March 2026.</p>\n<p>Total registered share capital remained unchanged at 88.88 million H shares with a par value of RMB 1 each. No issues, cancellations, conversions, repurchases or treasury share movements occurred during the period, leaving issued shares and treasury shares at 88.88 million and zero, respectively.</p>\n<p>The company confirmed that its public float exceeded the initial prescribed threshold of 17.05% of issued H shares, meeting Main Board Rule 13.32B requirements.</p>\n<p>DIAGENS-B reported no outstanding share options, warrants, convertible instruments or other equity-linked agreements as of 31 March 2026.</p>\n<p>Executive Director Song Ning signed the statutory confirmations that all regulatory, legal and listing conditions related to the company’s securities have been fully observed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DIAGENS-B March 2026 Monthly Return Shows Stable Share Base and Public Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDIAGENS-B March 2026 Monthly Return Shows Stable Share Base and Public Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-22 17:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) filed a resubmitted monthly return with Hong Kong Exchanges and Clearing on 22 April 2026, covering the period to 31 March 2026—the company’s first reporting period after its Main Board debut on 30 March 2026.</p>\n<p>Total registered share capital remained unchanged at 88.88 million H shares with a par value of RMB 1 each. No issues, cancellations, conversions, repurchases or treasury share movements occurred during the period, leaving issued shares and treasury shares at 88.88 million and zero, respectively.</p>\n<p>The company confirmed that its public float exceeded the initial prescribed threshold of 17.05% of issued H shares, meeting Main Board Rule 13.32B requirements.</p>\n<p>DIAGENS-B reported no outstanding share options, warrants, convertible instruments or other equity-linked agreements as of 31 March 2026.</p>\n<p>Executive Director Song Ning signed the statutory confirmations that all regulatory, legal and listing conditions related to the company’s securities have been fully observed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02526","symbol_name":"德适-B","start_time":0,"source_url":"","article_id":"1175371587","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175371587","pubTimestamp":1776848882,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) filed a resubmitted monthly return with Hong Kong Exchanges and Clearing on 22 April 2026, covering the period to 31 March 2026—the company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02526":"德适-B"},"translate_title":"Diagens-B 2026年3月月报表显示稳定的股份基础和公众持股量合规性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02526":1},"content_text":"Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) filed a resubmitted monthly return with Hong Kong Exchanges and Clearing on 22 April 2026, covering the period to 31 March 2026—the company’s first reporting period after its Main Board debut on 30 March 2026.\nTotal registered share capital remained unchanged at 88.88 million H shares with a par value of RMB 1 each. No issues, cancellations, conversions, repurchases or treasury share movements occurred during the period, leaving issued shares and treasury shares at 88.88 million and zero, respectively.\nThe company confirmed that its public float exceeded the initial prescribed threshold of 17.05% of issued H shares, meeting Main Board Rule 13.32B requirements.\nDIAGENS-B reported no outstanding share options, warrants, convertible instruments or other equity-linked agreements as of 31 March 2026.\nExecutive Director Song Ning signed the statutory confirmations that all regulatory, legal and listing conditions related to the company’s securities have been fully observed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175371587","isCrawlerRequest":true}